Infusion business appears to be the only profitable part of AHZ ATM - nuts and bolts part of business - really just an Australian based agency for the hardware and consumables.
ADAPT stuff has potential but slowly getting market share - surgeons don't change their ways in a hurry- all new products will need time in market for acceptance
Immunotherapy division - was the blue sky imho - but recent vaccine results not great and a fair bit of cash been thrown this way
A definite US bias developing - directors, reporting etc .
PERHAPS grand plan is :
Sell infusion business - simple - probably to Australian based business in same field. Easily quantifiable
Give way immunotherapy- write off ( unsure if any value obtainable by selling )
Grind away at ADAPT products and eventually get bought out by a bigger player ( US based company in medical devices) but probably when cash strapped. Jobs for the boys included
Result for shareholders- hmmmmmmm !
Any way these are just my ramblings and probably won't happen but gives good for thought
- Forums
- ASX - By Stock
- AVR
- Revenue $m
Revenue $m, page-23
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $326.7M |
Open | High | Low | Value | Volume |
$17.00 | $17.44 | $16.95 | $169.0K | 9.937K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1460 | $17.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.10 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1460 | 17.000 |
1 | 27 | 16.970 |
1 | 13 | 16.960 |
1 | 196 | 16.950 |
1 | 682 | 16.910 |
Price($) | Vol. | No. |
---|---|---|
17.100 | 1 | 1 |
17.110 | 129 | 2 |
17.490 | 315 | 2 |
17.500 | 500 | 1 |
17.750 | 2141 | 1 |
Last trade - 14.21pm 19/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |